{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T10:57:17Z","timestamp":1776423437464,"version":"3.51.2"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1097\/icl.0000000000000001","type":"journal-article","created":{"date-parts":[[2014,1,14]],"date-time":"2014-01-14T04:39:30Z","timestamp":1389674370000},"page":"79-83","source":"Crossref","is-referenced-by-count":25,"title":["Topical Tacrolimus 0.03% as Sole Therapy in Vernal Keratoconjunctivitis"],"prefix":"10.1097","volume":"40","author":[{"given":"Guilherme Gubert","family":"M\u00fcller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Newton Kara","family":"Jos\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosane Silvestre","family":"de Castro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-4-20210128","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/sj.eye.6700675","article-title":". Vernal keratoconjunctivitis.","volume":"18","author":"Bonini","year":"2004","journal-title":"Eye (Lond)"},{"key":"R2-4-20210128","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1755-3768.2008.01347.x","article-title":"Vernal keratoconjunctivitis: A major review.","volume":"87","author":"Kumar","year":"2009","journal-title":"Acta Ophthalmol"},{"issue":"Suppl","key":"R3-4-20210128","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0039-6257(93)90035-6","article-title":"Conjunctivitis of allergic origin: Clinical presentation and differential diagnosis.","volume":"38","author":"Friedlaender","year":"1993","journal-title":"Surv Ophthalmol"},{"key":"R4-4-20210128","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.preteyeres.2005.09.002","article-title":". Role of structural cells of the cornea and conjunctiva in the pathogenesis of vernal keratoconjunctivitis.","volume":"25","author":"Kumagai","year":"2006","journal-title":"Prog Retin Eye Res"},{"key":"R5-4-20210128","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1097\/00130832-200310000-00011","article-title":"Allergic chronic inflammation of the ocular surface in vernal keratoconjunctivitis.","volume":"3","author":"Bonini","year":"2003","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"Suppl","key":"R6-4-20210128","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0039-6257(93)90036-7","article-title":"Conjunctivitis of allergic origin: Immunologic mechanisms and current approaches to therapy.","volume":"38","author":"Abelson","year":"1993","journal-title":"Surv Ophthalmol"},{"key":"R8-4-20210128","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1590\/S0004-27492011000600016","article-title":". Ocular allergy Latin American consensus.","volume":"74","author":"Santos","year":"2011","journal-title":"Arq Bras Oftalmol"},{"key":"R9-4-20210128","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S1350-9462(02)00006-X","article-title":"Vernal keratoconjunctivitis: Pathogenesis and treatment.","volume":"21","author":"Leonardi","year":"2002","journal-title":"Prog Retin Eye Res"},{"key":"R10-4-20210128","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0161-6420(00)00092-0","article-title":". Vernal keratoconjunctivitis revisited: A case series of 195 patients with long-term followup.","volume":"107","author":"Bonini","year":"2000","journal-title":"Ophthalmology"},{"key":"R11-4-20210128","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/00055735-200012000-00016","article-title":"Ocular complications of topical, peri-ocular, and systemic corticosteroids.","volume":"11","author":"Carnahan","year":"2000","journal-title":"Curr Opin Ophthalmol"},{"key":"R12-4-20210128","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1159\/000080937","article-title":"Immunomodulatory therapy in ophthalmology: Is there a place for topical application O","volume":"218","author":"Bertelmann","year":"2004","journal-title":"phthalmologica"},{"key":"R13-4-20210128","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.7164\/antibiotics.40.1249","article-title":". FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics.","volume":"40","author":"Kino","year":"1987","journal-title":"J Antibiot (Tokyo)"},{"key":"R14-4-20210128","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2165\/11587010-000000000-00000","article-title":". Tacrolimus in the treatment of ocular diseases.","volume":"25","author":"Zhai","year":"2011","journal-title":"BioDrugs"},{"key":"R15-4-20210128","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1016\/j.transproceed.2005.08.040","article-title":". Tacrolimus (FK506) versus cyclosporine microemulsion (neoral) as maintenance immunosuppression therapy in kidney transplant recipients.","volume":"37","author":"Abou-Jaoude","year":"2005","journal-title":"Transplant Proc"},{"key":"R16-4-20210128","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0140-6736(02)11196-2","article-title":". Tacrolimus versus microemulsified ciclosporin in liver transplantation: The TMC randomised controlled trial.","volume":"360","author":"OGrady","year":"2002","journal-title":"Lancet"},{"key":"R17-4-20210128","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1517\/14740330902969441","article-title":"Long-term safety of tacrolimus ointment in atopic dermatitis.","volume":"8","author":"Remitz","year":"2009","journal-title":"Expert Opin Drug Saf"},{"key":"R18-4-20210128","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1097\/ICO.0b013e31823f8c9b","article-title":". Clinical treatment of dry eye using 0.03 tacrolimus eye drops.","volume":"31","author":"Moscovici","year":"2012","journal-title":"Cornea"},{"key":"R20-4-20210128","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/01.ico.0000151507.49565.6e","article-title":"Topical tacrolimus ointment for treatment of refractory anterior segment inflammatory disorders.","volume":"24","author":"Joseph","year":"2005","journal-title":"Cornea"},{"key":"R21-4-20210128","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.ajo.2012.12.009","article-title":"Application for tacrolimus ointment in treating refractory inflammatory ocular surface diseases.","volume":"155","author":"Lee","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"R22-4-20210128","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.ophtha.2007.07.025","article-title":". Therapeutic effects of tacrolimus ointment for refractory ocular surface inflammatory diseases.","volume":"115","author":"Miyazaki","year":"2008","journal-title":"Ophthalmology"},{"key":"R23-4-20210128","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1089\/jop.2009.0087","article-title":". A randomized, placebo-controlled clinical trial of tacrolimus ophthalmic suspension 0.1 in severe allergic conjunctivitis.","volume":"26","author":"Ohashi","year":"2010","journal-title":"J Ocul Pharmacol Ther"},{"key":"R24-4-20210128","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/eye.2011.75","article-title":". Topical 0.005 tacrolimus eye drop for refractory vernal keratoconjunctivitis.","volume":"25","author":"Kheirkhah","year":"2011","journal-title":"Eye (Lond)"},{"key":"R25-4-20210128","first-page":"177","article-title":". A double-masked comparison of 0.1 tacrolimus ointment and 2 cyclosporine eye drops in the treatment of vernal keratoconjunctivitis in children.","volume":"30","author":"Labcharoenwongs","year":"2012","journal-title":"Asian Pac J Allergy Immunol"},{"key":"R26-4-20210128","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/1523-1747.ep12614216","article-title":". Anti-inflammatory effect of FK-506 on human skin mast cells.","volume":"99","author":"de Paulis","year":"1992","journal-title":"J Invest Dermatol"},{"key":"R27-4-20210128","first-page":"574","article-title":"Tacrolimus: The drug for the turn of the millennium Arch D","volume":"135","author":"Ruzicka","year":"1999","journal-title":"ermatol"},{"key":"R28-4-20210128","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1080\/02713680802149115","article-title":". Topical tacrolimus 0.03 ointment for intractable allergic conjunctivitis: An open-label pilot study.","volume":"33","author":"Attas-Fox","year":"2008","journal-title":"Curr Eye Res"},{"key":"R29-4-20210128","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1097\/ICO.0b013e3181d83875","article-title":". Topical tacrolimus ointment for treatment of intractable atopic keratoconjunctivitis: A case report and review of the literature.","volume":"30","author":"Garcia","year":"2011","journal-title":"Cornea"},{"key":"R30-4-20210128","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/ICO.0b013e318159afbb","article-title":". Tacrolimus ointment 0.03 in the eye for treatment of giant papillary conjunctivitis.","volume":"27","author":"Kymionis","year":"2008","journal-title":"Cornea"},{"key":"R31-4-20210128","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1097\/ICO.0b013e318243f69d","article-title":"Tacrolimus ointment 0.03 for treatment of refractory childhood phlyctenular keratoconjunctivitis.","volume":"31","author":"Kymionis","year":"2012","journal-title":"Cornea"},{"key":"R32-4-20210128","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1136\/bjo.2009.172387","article-title":". Topical tacrolimus 0.03 monotherapy for vernal keratoconjunctivitis-Case series.","volume":"94","author":"Tam","year":"2010","journal-title":"Br J Ophthalmol"},{"key":"R33-4-20210128","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0011-393X(04)90032-X","article-title":"Double-masked, randomized, parallel-group study comparing olopatadine 0.1 ophthalmic solution with cromolyn sodium 2 and levocabastine 0.05 ophthalmic preparations in children with seasonal allergic conjunctivitis.","volume":"65","author":"Ciprandi","year":"2004","journal-title":"Curr Ther Res Clin E"},{"key":"R34-4-20210128","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0149-2918(02)85042-1","article-title":"Randomized, double-masked, placebo-controlled comparison of the efficacy of emedastine difumarate 0.05 ophthalmic solution and ketotifen fumarate 0.025 ophthalmic solution in the human conjunctival allergen challenge model.","volume":"24","author":"DArienzo","year":"2002","journal-title":"Clin Ther"},{"key":"R35-4-20210128","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1016\/S0149-2918(03)80217-5","article-title":". Randomized, double-masked comparison of olopatadine ophthalmic solution, mometasone furoate monohydrate nasal spray, and fexofenadine hydrochloride tablets using the conjunctival and nasal allergen challenge models.","volume":"25","author":"Spangler","year":"2003","journal-title":"Clin Ther"},{"key":"R36-4-20210128","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.ophtha.2009.11.043","article-title":". Tailored approach to the treatment of vernal keratoconjunctivitis.","volume":"117","author":"Sacchetti","year":"2010","journal-title":"Ophthalmology"},{"key":"R37-4-20210128","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1007\/s11882-013-0345-0","article-title":"Use of cyclosporine A and tacrolimus in treatment of vernal keratoconjunctivitis.","volume":"13","author":"Vichyanond","year":"2013","journal-title":"Curr Allergy Asthma Rep"},{"key":"R38-4-20210128","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jaci.2003.10.065","article-title":". Vernal keratoconjunctivitis: Result of a novel therapy with 0.1 topical ophthalmic FK-506 ointment.","volume":"113","author":"Vichyanond","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"R39-4-20210128","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s10384-004-0187-3","article-title":". Comparison of topical dexamethasone and topical FK506 treatment for the experimental allergic conjunctivitis model in BALBc mice.","volume":"49","author":"Shoji","year":"2005","journal-title":"Jpn J Ophthalmol"}],"container-title":["Eye & Contact Lens: Science & Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/ICL.0000000000000001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:59:09Z","timestamp":1620953949000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00140068-201403000-00004"}},"subtitle":["A Randomized Double-Masked Study"],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/icl.0000000000000001","relation":{},"ISSN":["1542-2321"],"issn-type":[{"value":"1542-2321","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]}}}